EFFECTIVENES OF SPIRONOLACTON IN COMPLEX THERAPY OF RHEUMATOID ARTHRITIS
Abstract
Aldosterone blocker – Spironolactone has anti-inflammatory, anti-proliferative and anti-oxidative effects, that is why pathogenetically it is expedient to use it in complex therapy of rheumatoid arthritis.
Material and methods: 46 patients with RA took 25-50 mg/day of Spironolactone during 12 months as an addition to standard therapy, the comparison group consisted of 47 patients that got only standard therapy, all the patients were fully examined prior and post the treatment.
Results: complex RA therapy leads to improved VAS, HAQ, the antioxidative potential index F; decreased blood concentrations of TNF-α, ICAM-1, FGF and VEGF in contrast to standard therapy. Complex therapy made reduced the DAS 28 more > 0.6.
Conclusions: applying of Spironolactone in complex therapy of rheumatoid arthritis contributes to more pronounced improvement in indices of articular syndrome and patient’s life quality, reduce of anti-inflammatory, anti-proliferative and angiogenic cytokines, and more effectively reduces the activity of the disease comparing to standard therapy.
References
Bendtzen, K., Hansen, P.R., Rieneck, K. (2003). Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-a and interferon-g, and has potential in the treatment of arthritis. Clinical and Experimental Immunology, 134, 151–158.
Delcayre, C., Swynghedauw B. (2002). Molecular mechanisms of myocardial remodelling. The role of aldosterone. Journal of Molecular and Cellular Cardiology, 34, 1577-1584.
Giatromanolaki, A., Sivridis, E., Maltezos, E., Athanassou, N., Papazoglou, D., Gatter, K. C., Harris, A. L. and Koukourakis, M. I. (2003). Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Research and Therapy, 5(4), 193-201.
Guidelines for the Management of Rheumatoid Arthritis: 2002 Update. Arthritis & Rheumatism, 46 (2), 328346.
Huber, L.C., Distler, O., Tarnerl, I., Gay, R.E., Gay, S., Pap, T. (2006). Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology, 45, 669–675.
Kalden, J.R., Schattenkirchner, M., Sörensen, H., Emery, P., Deighton, C., Rozman, B., Breedveld, F. (2003). The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arthritis & Rheumatism, 48 (6), 151320.
Klimiuk, P.A., Sierakowski, S., Latosiewicz, R., Cylwik, J.P., Cylwik, B., Skowronski, J., Chwiecko, J. (2002). Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Annals Rheumatic Diseases, 61 (9), 804-809.
Malemud, C.J. (2007). Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clinica Chimica Acta, 375, 10-19.
Paleolog, E. (2004). Hypoxia: not merely a regulator of angiogenesis? Arthritis Research and Therapy, 6 (2), 75-77.
Romas, E., Gillespie, M.T., Martin, T.J. (2002). Involvement of RANK ligand and TNF-alpha in bone destruction in rheumatoid arthritis. Bone, 30, 340 346.
Rombouts, K., Wielant, A., Hellemans, K., Schuppan, D., Geerts, A. (2001). Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. British Journal of Pharmacology, 134(1), 224–232.
Sugiyama, T., Yoshimoto, T., Hirono, Y., Suzuki, N., Sakurada, M., Tsuchiya, K., Minami, I., Iwashima, F., Sakai, H., Tateno, T., Sato, R., Hirata, Y. (2005). Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochemical and Biophysical Research Communications, 336, 163-167.
Sønder, S.U., Mikkelsen, M., Rieneck, K., Hedegaard, C.J., Bendtzen, K. (2006). Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. British Journal of Pharmacology, 148 (1), 46–53.
Copyright information
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
info@cbuni.cz, www.cbuni.cz, ojs.journals.cz
